Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.66 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 6/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 6/20 | 0.43 |
| ▸ | PSMB9 | P28065 | 3/20 | 0.43 |
| ▸ | JAK1 | P23458 | 5/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30364083 | 1.00 | SMYD3 (0.66) | SMYD3SMYD2IRAK4PSMB8PSMB5 | |
| SCHEMBL31009899 | 0.91 | SMYD3 (0.53) | SMYD3IRAK4PSMB8PSMB5PSMB9 | |
| SCHEMBL29341710 | 0.91 | SMYD3 (0.53) | SMYD3IRAK4PSMB8PSMB5PSMB9 | |
| SCHEMBL3378354 | 0.89 | SMYD3 (0.52) | SMYD3IRAK4PSMB8PSMB5PSMB9 | |
| SCHEMBL3378349 | 0.89 | SMYD3 (0.52) | SMYD3IRAK4PSMB8PSMB5PSMB9 | |
| SCHEMBL3378158 | 0.85 | SMYD3 (0.48) | SMYD3IRAK4JAK1JAK2TYK2 | |
| SCHEMBL3378161 | 0.85 | SMYD3 (0.48) | SMYD3IRAK4JAK1JAK2TYK2 | |
| SCHEMBL29341711 | 0.84 | SMYD3 (0.45) | SMYD3IRAK4JAK1JAK2TYK2 | |
| SCHEMBL17591800 | 0.84 | SMYD3 (0.57) | SMYD3SMYD2PSMB8PSMB5PSMB9 | |
| SCHEMBL28857831 | 0.80 | SMYD3 (0.64) | SMYD3SMYD2PSMB8PSMB5PSMB9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | disclosed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | disclosed |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | Epizyme, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170355695-A1 | SMYD Inhibitors | Epizyme, Inc. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355695-A1 | SMYD Inhibitors | Epizyme, Inc. (US) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | SMYD3, SMYD2, SNRPD3 | SMYD3 1/4885SMYD2 2/4885IRAK4 3693/4885 |
| US-20170355695-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | SMYD3 1/4885SMYD2 2/4885IRAK4 4203/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | SMYD3 1/4885SMYD2 2/4885IRAK4 4188/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | SMYD3 2/4885SMYD2 1/4885IRAK4 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.